For its high youth employment rate and best practice, MMB has been selected the best employer by the Seongnam City Council, which oversees Pangyo Technovalley where MMB Korea office is located.

MediMabBio has made a contract with a leading global CDMO Thermo Fisher Scientific to take the first step towards clinical trial approval with its first pipeline, MMB101. The MMB101 product is a monoclonal antibody that targets immune checkpoints. Through the new Quick to Clinic Solution of Thermo Fisher Scientific, MediMabBio plans to accelerate cell line and process development. Also, both companies will collaborate to manufacture drug substances and drug products for clinical trials.

MediMabBio has launched the first project to test its main pipelines (i.e. MMB101, MMB102) globally by partnering with University Hospitals of Birmingham, which have conducted the largest number of clinical trials of liver-related diseases in UK. MediMabBio plans to expand the collaboration with the University Hospitals in areas of autoimmune diseases and NASH treatment.

MMB has successfully completed a Series-A fundraising with 18 million USD in February 2021. 7 investors have participated with current investors following-on. There are 15 people in Korea and UK offices currently with more than 90 percent of them holding Masters and doctoral degrees. Two of their pipelines, MMB 101 and MMB 102, are expected to enter into pre-clinical study at the end of this year, and one of the pipelines, MMB 201, at the beginning of next year.

Based on its newly established UK office, MediMabBio will intensify its R&D collaborations with universities and hospitals in UK, including the University of Oxford and Birmingham University, for the purpose of expanding its pipeline development and technology transfers.

The power of big conglomerates is enormous in Korean economy. In bio venture field, networks amongst researchers from big conglomerates are powerful. Researchers who used to belong to big conglomerates have fast developed new biotechnology by starting up bio ventures.

MediMabBio, a bio venture start-up company based in Korea and UK, has attracted 3,000,000 USD for Pre-series A investment. MediMabBio, has closed the investment from Smilegate Investment and BNH Investment on 15 of February.

Four venture start-ups including MediMabBio, incubated by Ulsan Creative Economy Innovation Center, have received TIPS (Tech Incubator Program for Startup Korea) investment.